Loading
A phase 2 trial of Adebrelimab, Carboplatin, Cisplatin and SHR-8068 in advanced solid tumours, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.
A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer is a phase 2 interventional study registered as NCT07241767 by Jiangsu HengRui Medicine Co., Ltd., with 200 participants planned, started 2025-11-12 and due to reach its primary completion in 2027-11. Interventions recorded: FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin, FH-006 ; SHR-1316 ; BP102 and FH-006; SHR-1316 ; SHR-8068.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Carboplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.